Results 241 to 250 of about 97,116 (340)
Study of stress‐strain loops on cardiotoxicity related to immune checkpoint inhibitors [PDF]
Shi Chunlan, Bing Yue, Xi Wei
openalex +1 more source
Their bioactive constituents act through antioxidant, anti‐inflammatory, and metabolic‐regulating mechanisms, validating their classification as functional foods. Evidence from clinical and biochemical studies largely supports these benefits, although some claims stem from preliminary or in vitro findings.
Nighat Raza +7 more
wiley +1 more source
Redefining cardiac risk in breast radiotherapy: a substructure-based dosimetric and biomarker correlation study. [PDF]
Nair RP +9 more
europepmc +1 more source
Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
Huimin Hu +4 more
openalex +1 more source
ABSTRACT Background Doxorubicin (DOX) is a highly effective chemotherapeutic agent whose use can cause respiratory toxicity, increasing patient fatigue and negatively impacting quality of life and survival. These adverse effects occur due to diaphragm muscle mitochondrial accumulation of DOX, where it causes reactive oxygen species production and iron ...
Ashley J. Smuder +4 more
wiley +1 more source
Dapagliflozin alleviates sunitinib-induced cardiotoxicity through AMPKα-PPARα axis and enhances the sensitivity of renal cell carcinoma to sunitinib. [PDF]
Huang SY +7 more
europepmc +1 more source
Current Trends in Duchenne Muscular Dystrophy Research and Therapy: 3D Cardiac Modelling
ABSTRACT Duchenne muscular dystrophy (DMD), caused by dystrophin deficiency, presents a multifaceted challenge that affects both skeletal muscle function and cardiomyocyte homeostasis, causing progressive degeneration and life‐threatening cardiac complications by adolescence.
Marta Przymuszała +3 more
wiley +1 more source
Delayed Cardiac Dysfunction During Prolonged Use of Trastuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. [PDF]
Chen X +8 more
europepmc +1 more source
Triple HER2 blockade with trastuzumab, pertuzumab, and pyrotinib (TPPy) did not improve total pathological complete response (tpCR) rates or breast pathological complete response (bpCR) rates compared with dual blockade with trastuzumab and pertuzumab (TP), but was associated with greater grade ≥ 3 toxicity, particularly diarrhea.
Jiahui Huang +17 more
wiley +1 more source

